| Type | Title | Date Released | |
|---|---|---|---|
6-K | Satellos Changes Primary Efficacy Endpoint in BASECAMP Phase 2 Pediatric Trial to MRI-Measured Fat Fraction Following FDA Feedback | ||
6-K | Satellos to Host Investor Call to Provide Update on Clinical and Regulatory Strategy for BASECAMP Phase 2 Pediatric Study | ||
6-K | Satellos Establishes Scientific Advisory Board to Explore Regeneration in Aging and Neuroscience | ||
6-K | Satellos Bioscience to Participate in November Investor Conferences and Highlights Clinical Progress | ||
6-K | Satellos Granted Composition of Matter Patent for Forazapadin | ||
6-K | Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy | ||
6-K | Satellos Bioscience Announces FDA Clearance of IND Application for Forazapadin in FSHD and Non-Dilutive Financing Partnership | ||
6-K | Satellos to Present Four Scientific Posters on Forazapadin (SAT-3247) at the 31st Annual Congress of the World Muscle Society | ||
6-K | Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247 | ||
6-K | Satellos Bioscience to Participate in September 2026 Investor Conferences | ||
6-K | Satellos Bioscience Inc. Enters into $50 Million "At-the-Market" Equity Offering Sales Agreement | ||
SUPPL | Form SUPPL |
